KPI-285

N/A

Report date: 2025/06/11 11:01:23
NME

Base Information

Drug NameKPI-285
Drug Alias NameReceptor Tyrosine Kinase Inhibitor (Kala Pharmaceuticals)K-106KPI-285
ClassificationSmall molecules
Mechanisms of ActionVascular endothelial growth factor receptor antagonistsNerve growth factor receptor Trk-A inhibitors
TargetsNerve growth factor receptor Trk-AVascular endothelial growth factor receptor
Therapy Area/IndicationsWet age-related macular degenerationRetinal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKALA BIO Inc
China Registration ClassN/A

Develop Information

Active CompaniesKALA BIO Inc
Inactive CompaniesN/A
Active IndicationsWet age-related macular degenerationRetinal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A